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Editorial
Little to learn from phase II trials in small-cell lung cancer
Small-cell lung cancer (SCLC) is the classic example of
a chemosensitive solid tumor in which a dose-response
relation has been demonstrated [1]. Despite high re-
sponse rates with standard combination chemotherapy,
overall survival remains poor [2]. With the aim to over-
come drug resistance high dose chemotherapy has been
extensively investigated for two decades. A multitude of
small phase II trials revealed contradictory results. Most
of these trials comprised small patient numbers with
heterogeneous prognostic factors [3] and did not allow
the detection of small, but valuable improvements. More
recently intensification has been facilitated with the avail-
ability of hematopoetic growth factors and progenitor
cell support, leading again to many phase I—II trials. Yet,
another phase II trial is presented in this issue of Annals
of Oncology by van de Velde et al. [4]. These investiga-
tors administered 4 alternating cycles of ifosfamide-
epirubicin and carboplatin-etoposide to 35 patients
with limited stage small-cell lung cancer. Concomitant
but split course once daily radiotherapy was given for
five days during each cycle of chemotherapy. At a median
follow-up of almost 4 years they report an overall
median survival of 25 months and an actuarial three-
year survival of 36%. These results are impressive when
compared to other standard or intensive regimens, but
was this outcome due to intensive chemotherapy? The
regimen they used with stem-cell support can also be
administered with growth factors alone, as shown in
their trial for the first cycle. Dose escalation was moder-
ate and consisted mainly of doubling the dose of ifosfa-
mide and carboplatin, while maintaining standard doses
of etoposide and epirubicin. Based solely on the chemo-
therapy, this regimen cannot be considered intensive.
The expected conclusions from this type of phase II
trials are feasibility and the claim for a future random-
ized trial, which only rarely follows. At this years ASCO
meeting again two such trials were reported [5, 6], at a
time when randomized trials have already been com-
pleted [7-13] or are ongoing. Some definite conclusions
can be drawn from the two largest and most recent trials
[12, 13]. Stewart et al. randomized 300 patients to either
standard or intensified V-ICE (vincristine, ifosfamide,
carboplatin, etoposide) [12]. Chemotherapy was admin-
istered for six cycles every four weeks in the standard
arm, and every three weeks in the intensified arm (in-
crease in dose intensity of 25%). Although the complete
remission rates were comparable, the median survival
was 16 months in the high-dose arm and only 12.5
months in the standard arm. At two years this translated
into almost twice as many patients being alive (33% vs.
18%). An even larger trial conducted by the MRC with
over 400 patients was reported in abstract form showing
an improved survival already at one year [13]. In all
these studies the increase in dose intensity was only
moderate reaching 33% at the most. This is far from the
300%-500%, what should be obtained according to in
vitro modeling [14]. This intensity can be obtained in the
clinic as demonstrated in a multicenter trial [15]. Sixty-
nine patients were treated with three cycles of a high-
dose ICE-regimen (ifosfamide, carboplatin, etoposide)
with peripheral stem-cell support and a relative dose-
intensity of 290% was achieved compared to the standard
ICE-regimen. This intensive regimen is currently com-
pared to six cycles of standard ICE in a randomized
international multicenter trial by the European Group
for Blood and Marrow Transplantation. The primary
endpoint in this trial is long-term survival and thus
possibly cure at three years.
Accelerating the radiation therapy is another way to
increase treatment intensity. Indeed, a recently reported
large randomized trial in selected patients with limited
disease (exclusion of N3 and pleural effusion) showed
significantly higher two- and five-year survival rates
after hyperfractionated twice daily radiotherapy (2 x
1.5 Gy, 45 Gy) versus the same total dose delivered once
daily (1.8 Gy) [16]. Radiation therapy was given over a
period of three weeks in the experimental arm, and over
five weeks in the standard arm. All patients received
concomitant chemotherapy and radiation was begun
together with the first cycle of chemotherapy. Median
survival was 23 vs. 19 months, and at 5 years the actuarial
survival was 26% for patients receiving twice daily vs.
16% only for patients with once daily radiotherapy. There
is now the need to develop a concept of treatment intensi-
fication in SCLC not only focused on chemotherapy, but
on an overall strategy of intensive concomitant chemo-
radiotherapy with optimal delivery of all modalities. The
study by van de Velde et al. was an attempt in that
direction [4]. Unfortunately neither the chemotherapy
nor the radiation therapy were sufficiently intensive as
documented by the very low rate of mucosal toxicity.
Recurrence in the brain remains a major site of treat-
ment failure. The randomized NCIC trial suggested that
the failure in the brain be closely related to the early
control of the primary disease [17]. In patients receiving
late concomitant chemoradiotherapy brain metastases
could be detected on CT scan prior to PCI twice as
frequently than in patients treated with early radiation.
Accordingly, the risk of developing brain metastases
during the course of disease was 28% and 18% for pa-
tients treated with late and early radiation, respectively.
This suggests that CNS recurrence can be reduced by
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more early intensive treatment at the primary site at
least in patients with limited stage. High-dose chemo-
therapy may in part overcome the blood-brain barrier.
Several new and active drugs have become available for
the treatment of SCLC. In particular topotecan may be
of interest for the treatment of occult CNS disease.
Topotecan has a good penetration into the CSF and can
also be given intrathecally [18, 19]. This drug should be
integrated into current standard and intensive regimens.
For the future, innovative treatments remain to be
explored. Indeed, despite improvements and impressive
complete response rates, a majority of patients continue
to die of their disease. Too few patients are cured by
present therapies and strategies against minimal resid-
ual disease should be studied. Neither maintenance
chemotherapy [20, 21], nor adjuvant interferons [22, 23]
seemed to lower the recurrence rate. Immunotherapy
using anti-idiotype antibody BEC2, mimicking the
ganglioside GD3 present on the majority of the tumor
cells, combined with BCG, increased dramatically the
relapse-free survival of a small number of patients with
limited disease responding to chemotherapy [24]. After
a median follow-up of 47 months, only one of seven
patients with limited stage disease relapsed. Obviously
confirmation is needed in a large randomized trial cur-
rently conducted by the EORTC. Other approaches are
undergoing phase III trials, like the adjuvant use of the
matrix metalloproteinase inhibitor marimastat, or BAY
12-9566, a new anti-angiogenesis compound. Vascular
endothelial growth factor (VEGF) has an important
role in tumor angiogenesis and VEGF has been associ-
ated with poor response to treatment and short survival
[25]. Agents blocking VEGF are in clinical development.
Modulation of radiation and drug resistance by interfer-
ing with apoptotic mechanisms may be another avenue
to be explored. Antisense oligodeoxynucleotide targeted
against c-myc or bcl-2 have been shown to reduce the
viability, to facilitate apoptosis and to increase the sensi-
tivity to chemotherapy [26, 27]. Such a treatment has
already been tested in lymphoma [28] and remains to be
evaluated in SCLC. The use of antibodies against auto-
crine growth factors or cell surface antigens, linked to a
toxin, has already been tested in the clinic with some
efficacy in relapsed SCLC [29].
Even if currently available treatment options for pa-
tients with SCLC remain unsatisfactory, only continu-
ous and rigorous research will lead to improvement.
Clinical research has to be conducted in an orderly and
timely fashion with a rapid transition from toxicity and
feasibility trials to well controlled clinical investigation.
Too much time, energy, money and ultimately patients
are lost in small, inconclusive phase II studies, when
progress will come only from well designed, and suffi-
ciently powered randomized trials.
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